|
業務類別
|
Biotechnology |
|
業務概覽
|
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases. |
| 公司地址
| 215 First Street, Suite 415, Cambridge, MA, USA, 02142 |
| 電話號碼
| +1 617 274-4000 |
| 傳真號碼
| +1 800 621-5203 |
| 公司網頁
| https://www.sarepta.com |
| 員工數量
| 835 |
| Ms. Louise Rodino-Klapac, PhD |
President, Research and Development and Technical Operations |
美元 666.71K |
16/07/2025 |
| Mr. Ian Michael Estepan |
President and Chief Operating Officer |
美元 656.96K |
16/07/2025 |
| Mr. Ryan H. Wong |
Executive Vice President, Chief Financial Officer and Principal Accounting Officer |
-- |
02/03/2026 |
| Ms. Cristin L. Rothfuss |
Executive Vice President, Chief General Counsel and Corporate Secretary |
-- |
24/04/2025 |
| Mr. Douglas S. Ingram,Esq. |
Director and Chief Executive Officer |
美元 846.90K |
25/02/2026 |
|
|
| Mr. Michael A. Chambers |
Independent Director |
02/03/2026 |
| Dr. Stephen L. Mayo, PhD |
Independent Director |
02/03/2026 |
| Dr. Kathryn Jean Boor, PhD |
Independent Director |
02/03/2026 |
| Mr. Richard J. Barry |
Independent Director |
02/03/2026 |
| Dr. Hans Wigzell, M.D.,PhD |
Independent Director |
02/03/2026 |
| Dr. Claude Nicaise,M.D. |
Independent Director |
02/03/2026 |
| Mr. Douglas S. Ingram,Esq. |
Director and Chief Executive Officer |
25/02/2026 |
| Ms. Deirdre P. Connelly |
Independent Director |
02/03/2026 |
| Dr. M. Kathleen Behrens Wilsey, PhD |
Chairwoman of the Board |
02/03/2026 |
|
|
|
|
